A cost minimization analysis of first-line polychemotherapy regimens in the treatment of advanced non-small cell lung cancer

被引：0
|
作者：
Le Lay, K
Avoinet, S
Chemali, N
Vergnenegre, A
Launois, R
机构：
[1] REES France, Paris, France
[2] Lilly France, F-92158 Suresnes, France
[3] CHU Limoges, Serv Informat Med, F-87042 Limoges, France
[4] Univ Paris 13, F-93017 Bobigny, France
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S255 / S255
页数：1
相关论文
共 50 条
  • [31] First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly
    Tania Losanno
    Cesare Gridelli
    [J]. Current Oncology Reports, 2021, 23
  • [32] Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer
    Myung Hee Chang
    Kyoung Ha Kim
    Hyun Jung Jun
    Hyo Song Kim
    Seong Yoon Yi
    Ji Eun Uhm
    Min Jae Park
    Do Hyoung Lim
    Sang Hoon Ji
    In Gyu Hwang
    Jeeyun Lee
    Yeon Hee Park
    Jin Seok Ahn
    Myung-ju Ahn
    Keunchil Park
    [J]. Cancer Chemotherapy and Pharmacology, 2009, 64 : 917 - 924
  • [33] Platinum doublets as first-line treatment for elderly patients with advanced non-small cell lung cancer
    Piacentini, Paolo
    Greco, Filippo
    Mercanti, Anna
    Trolese, Anna Rita
    Durante, Emilia
    Moratello, Giacomo
    Tognetto, Michele
    Furini, Lara
    Giuliani, Jacopo
    Bonetti, Andrea
    [J]. TUMORI JOURNAL, 2013, 99 (06): : 650 - 655
  • [34] First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer A Systematic Review
    Goffin, John
    Lacchetti, Christina
    Ellis, Peter M.
    Ung, Yee C.
    Evans, William K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (02) : 260 - 274
  • [35] Cost-effectiveness of gefitinib for first-line treatment of advanced non-small cell lung cancer: A Markov model-based analysis
    Liu, P. H.
    Hu, F. C.
    Wang, J. D.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A64 - A64
  • [36] LORLATINIB AS A FIRST-LINE TREATMENT FOR ALK plus ADVANCED NON-SMALL CELL LUNG CANCER: A COSTEFFECTIVENESS ANALYSIS IN SPAIN
    Presa, M.
    Vicente, D.
    Calles, A.
    Salinas-Ortega, L.
    Naik, J.
    Garcia, L. F.
    Soto, J.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S90 - S91
  • [37] Clinical Outcomes of First-line Therapies for Advanced Non-Small Cell Lung Cancer
    Garcia-Fumero, Ricardo
    Fernandez-Lopez, Cristina
    Calleja-Hernandez, Miguel angel
    Exposito-Ruiz, Manuela
    Espin, Jaime
    Exposito-Hernandez, Jose
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2023, 46 (10): : 433 - 438
  • [38] EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
    Fong, Thomas
    Morgensztern, Daniel
    Govindan, Ramaswamy
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (03) : 303 - 310
  • [39] Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand
    Limwattananon, Chulaporn
    Limwattananon, Supon
    Waleekhachonloet, Onanong
    Rattanachotphanit, Thananan
    [J]. LUNG CANCER, 2018, 120 : 91 - 97
  • [40] The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer
    Low, Jia Li
    Walsh, Robert J.
    Ang, Yvonne
    Chan, Gloria
    Soo, Ross A.
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
12345